Cue Biopharma (CUE) announced that Daniel Baker, M.D., will join Cue Biopharma as interim chief development officer effective November 25, 2024. Dr. Anish Suri will transition from his current role of president & chief scientific officer and will serve the company as principal research and immunology advisor effective as of the same date. Following his retirement from Janssen in 2019, Dr. Baker served as CEO and founder of Kira Therapeutics and more recently as Executive Director on the board of Galapagos Therapeutics from April 2022 until October 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CUE:
- CUE Upcoming Earnings Report: What to Expect?
- Cue Biopharma presents ‘positive’ update from Phase 1 trials of CUE-101, CUE-102
- Biotech Alert: Searches spiking for these stocks today
- Cue Biopharma announces pricing of $12M public offering
- Cue Biopharma announces common stock, warrant offering, no amount given
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue